Answers are grounded in this paper and cite their sources.
Based on available evidence, various international guidelines include the option to add HIPEC to interval CRS for patients with stage III ovarian cancer. The role of HIPEC in colorectal cancer is less well defined. Future studies will need to tailor patient selection, timing, and optimal regimens of HIPEC to improve the effectiveness of this specialized treatment in ovarian, colorectal, and other tumor types.
No takes yet. Share an insight, caveat, or question.
Stein et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: